Abstract:During the past few decades, intensive collaborative research in the fields of chronic and acute inflammatory disorders has resulted in a better understanding of the pathophysiology and diagnosis of these diseases. Modern therapeutic approaches are still not satisfactory and shock, sepsis and multiple organ failure remain the great challenge in intensive care medicine. However, the treatment of inflammatory diseases like rheumatoid arthritis, ulcerative colitis or psoriasis also represents an unresolved problem.Many factors contribute to the complex course of inflammatory reactions. Microbiological, immunological and toxic agents can initiate the inflammatory response by activating a variety of humoral and cellular mediators. In the early phase of inflammation, excessive amounts of interleukins and lipid-mediators are released and play a crucial role in the pathogenesis of organ dysfunction. Arachidonic acid (AA), the mother substance of the pro-inflammatory eicosanoids, is released from membrane phospholipids in the course of inflammatory activation and is metabolised to prostaglandins and leukotrienes.Various strategies have been evaluated to control the excessive production of lipid mediators on different levels of biochemical pathways, such as inhibition of phospholipase A2, the trigger enzyme for release of AA, blockade of cyclooxygenase and lipoxygenase pathways and the development of receptor antagonists against platelet activating factor and leukotrienes. Some of these agents exert protective effects in different inflammatory disorders such as septic organ failure, rheumatoid arthritis or asthma, whereas others fail to do so. Encouraging results have been obtained by dietary supplementation with long chain ω-3 fatty acids like eicosapentaenoic acid (EPA). In states of inflammation, EPA is released to compete with AA for enzymatic metabolism inducing the production of less inflammatory and chemotactic derivatives.

Real time changes in the expression of eicosanoid synthesizing enzymes during inflammation

Dynamic Eicosanoid Responses Upon Different Inhibitor and Combination Treatments on the Arachidonic Acid Metabolic Network.

The Eicosanoids, Redox-Regulated Lipid Mediators in Immunometabolic Disorders

Eicosanoids in inflammation in the blood and the vessel

Characterization of Eicosanoids Produced by Adipocyte Lipolysis

Mathematical Modeling of Eicosanoid Metabolism in Macrophage Cells: Cybernetic Framework Combined with Novel Information-Theoretic Approaches

Dynamic Simulations on the Arachidonic Acid Metabolic Network

Lipid Mediators in Inflammatory Disorders

Integrative Proteomic Analysis of Posttranslational Modification in the Inflammatory Response

Integrative Proteomic Analysis of Multiple Posttranslational Modifications in Inflammatory Response

Regulation of inflammation in cancer by dietary eicosanoids

Expression of Cyp2c/Cyp2j Subfamily Members and Oxylipin Levels During LPS‐induced Inflammation and Resolution in Mice

Old and new generation lipid mediators in acute inflammation and resolution

Directed Non-Targeted Mass Spectrometry and Chemical Networking for Discovery of Eicosanoids

The potential of acetylsalicylic acid and vitamin E in modulating inflammatory cascades in chickens under lipopolysaccharide-induced inflammation

Transcriptomic Analysis of Arachidonic Acid Pathway Genes Provides Mechanistic Insight into Multi-Organ Inflammatory and Vascular Diseases

Novel Aspects of Eicosanoid Signaling Through the Use of Gene-Targeted Mice

An adaptable in silico ensemble model of the arachidonic acid cascade

Self-Limited Versus Delayed Resolution of Acute Inflammation: Temporal Regulation of Pro-Resolving Mediators and MicroRNA

Recent Advances in the Methods and Applications Used to Analyze Eicosanoids